Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study.

IF 7.7 1区医学 Q1 CRITICAL CARE MEDICINE

Critical Care Medicine Pub Date : 2025-03-31 DOI:10.1097/CCM.0000000000006655

Manuela Iten, Kaspar Bachmann, Stephan M Jakob, Denis Grandgirard, Stephen L Leib, Luca Cioccari

{"title":"Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study.","authors":"Manuela Iten, Kaspar Bachmann, Stephan M Jakob, Denis Grandgirard, Stephen L Leib, Luca Cioccari","doi":"10.1097/CCM.0000000000006655","DOIUrl":null,"url":null,"abstract":"Objectives: Septic encephalopathy (SE) occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators. Commonly used sedative drugs, such as propofol and midazolam, may worsen neuronal inflammation. Dexmedetomidine (DEX) has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. The aim of this study was to investigate the effect of DEX on biomarkers associated with SE in critically ill patients with sepsis.Design: Pilot, open-label, randomized controlled clinical trial.Setting: Single-center University Hospital, Switzerland.Patients: Adult patients with sepsis admitted to the ICU, who required intubation and ongoing sedative medication between September 1, 2019, and June 30, 2022.Interventions: DEX-based sedation compared with propofol and/or midazolam-based sedation and serum S100-β level at 48 hr after randomization.Measurements and main results: The study included 70 participants with 34 (48.6%) randomized to the DEX group and 36 (51.4%) to the propofol/midazolam group. Median S100-β levels in the DEX group at 48 hr were 0.103 (interquartile range 0.052-0.194) ng/ml, and in the propofol/midazolam group 0.189 (0.086-0.368) ng/mL (p = 0.064). Other biomarker showed no differences over time. In patients with a Glasgow Coma Scale less than or equal to 13, the median S100-β level in the DEX group was 0.13 ng/mL (0.06-0.18) compared to 0.91 ng/mL (0.43-0.96) in the propofol/midazolam group (p = 0.033).Conclusions: DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation. The finding of lower S100-β levels in DEX-sedated patients with GCS less than 13 warrants further investigation.","PeriodicalId":10765,"journal":{"name":"Critical Care Medicine","volume":" ","pages":""},"PeriodicalIF":7.7000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical Care Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CCM.0000000000006655","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives: Septic encephalopathy (SE) occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators. Commonly used sedative drugs, such as propofol and midazolam, may worsen neuronal inflammation. Dexmedetomidine (DEX) has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. The aim of this study was to investigate the effect of DEX on biomarkers associated with SE in critically ill patients with sepsis.

Design: Pilot, open-label, randomized controlled clinical trial.

Setting: Single-center University Hospital, Switzerland.

Patients: Adult patients with sepsis admitted to the ICU, who required intubation and ongoing sedative medication between September 1, 2019, and June 30, 2022.

Interventions: DEX-based sedation compared with propofol and/or midazolam-based sedation and serum S100-β level at 48 hr after randomization.

Measurements and main results: The study included 70 participants with 34 (48.6%) randomized to the DEX group and 36 (51.4%) to the propofol/midazolam group. Median S100-β levels in the DEX group at 48 hr were 0.103 (interquartile range 0.052-0.194) ng/ml, and in the propofol/midazolam group 0.189 (0.086-0.368) ng/mL (p = 0.064). Other biomarker showed no differences over time. In patients with a Glasgow Coma Scale less than or equal to 13, the median S100-β level in the DEX group was 0.13 ng/mL (0.06-0.18) compared to 0.91 ng/mL (0.43-0.96) in the propofol/midazolam group (p = 0.033).

Conclusions: DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation. The finding of lower S100-β levels in DEX-sedated patients with GCS less than 13 warrants further investigation.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Care Medicine 医学-危重病医学

CiteScore

16.30

自引率

5.70%

发文量

728

审稿时长

2 months

期刊介绍： Critical Care Medicine is the premier peer-reviewed, scientific publication in critical care medicine. Directed to those specialists who treat patients in the ICU and CCU, including chest physicians, surgeons, pediatricians, pharmacists/pharmacologists, anesthesiologists, critical care nurses, and other healthcare professionals, Critical Care Medicine covers all aspects of acute and emergency care for the critically ill or injured patient. Each issue presents critical care practitioners with clinical breakthroughs that lead to better patient care, the latest news on promising research, and advances in equipment and techniques.